Merrill maintains Biogen at neutral

Biogen Idec. Inc. was kept at a neutral rating by Merrill Lynch analyst Eric Ende on news of early data from the Rituxan phase 2 trial in Multiple Sclerosis that showed a significant reduction in the number of lesions measured by MRI compared to a placebo. To estimate the Rituxan market opportunity, the analyst needs to see the drug's effect on time to relapse, number of flare-ups and reduction in disability. Shares of the Cambridge, Mass.-based pharmaceutical company were up 46 cents, or 1.04%, at $44.74, on volume of 2,194,890 shares versus the three-month running average of 3,105,390 shares. (Nasdaq: BIIB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.